SSSW(SH:688399)2025-04-29 11:00Financial Performance - The company's revenue for Q1 2025 was CNY 91,608,367.51, a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37%[5]. - Net profit attributable to shareholders decreased by 68.01% to CNY 12,819,431.90 compared to the same period last year[5]. - Total operating revenue for Q1 2025 was CNY 91,608,367.51, a slight increase of 0.54% compared to CNY 91,119,399.55 in Q1 2024[21]. - Net profit for Q1 2025 decreased to CNY 12,819,431.90, down 68.0% from CNY 40,067,958.01 in Q1 2024[22]. - Earnings per share for Q1 2025 was CNY 0.23, compared to CNY 0.68 in Q1 2024, reflecting a decline of 66.2%[23]. Cash Flow - The net cash flow from operating activities dropped by 91.92% to CNY 4,267,255.23, primarily due to reduced sales receipts and government subsidies[5][11]. - Cash flow from operating activities for Q1 2025 was CNY 4,267,255.23, a decrease of 91.9% from CNY 52,790,211.13 in Q1 2024[27]. - Cash inflow from investment activities was CNY 1,285,826,932.20, significantly higher than CNY 704,037,566.52 in Q1 2024[27]. - Cash outflow from investment activities surged to CNY 1,906,180,377.20, compared to CNY 383,193,683.36 in the previous year, indicating increased investment activity[27]. - Cash flow from financing activities increased to CNY 267,900,000.00 in Q1 2025, up from CNY 193,148,017.81 in Q1 2024[27]. Assets and Liabilities - Total assets increased by 3.46% to CNY 3,869,325,179.71 compared to the end of the previous year[6]. - The company's current assets decreased slightly to CNY 2,133,253,327.45 from CNY 2,139,295,851.19, indicating a reduction of about 0.28%[17]. - Total liabilities rose to CNY 605,873,720.44 from CNY 489,315,989.30, marking an increase of approximately 23.9%[18]. - The company's non-current assets increased to CNY 1,736,071,852.26 from CNY 1,600,652,165.48, reflecting a growth of about 8.5%[17]. - The total equity remained stable at CNY 3,263,451,459.27, unchanged from the previous reporting period[18]. Research and Development - Research and development expenses totaled CNY 19,092,486.00, accounting for 20.84% of revenue, a decrease of 0.85 percentage points from the previous year[6]. - The company reported a significant increase in research and development expenses, totaling CNY 19,092,486.00 for Q1 2025, compared to CNY 19,762,499.26 in Q1 2024[21]. Market and Pricing - Overseas revenue grew significantly by 69.00% due to prior product certifications and strategic deployment in international markets[7]. - The company faced pressure on product pricing due to the deep implementation of centralized procurement in the in vitro diagnostics industry[7]. - Government subsidies decreased year-on-year, contributing to the decline in net profit[7]. Other Financial Metrics - The basic earnings per share decreased by 66.18% to CNY 0.23, reflecting the decline in net profit[6][11]. - The weighted average return on equity fell by 0.78 percentage points to 0.39%[6]. - Cash and cash equivalents saw a significant decline, dropping to CNY 329,915,492.31 from CNY 810,632,720.07, a decrease of approximately 59.3%[16]. - The accounts receivable increased slightly to CNY 55,178,822.98 from CNY 53,822,041.97, showing a growth of about 2.5%[16]. - Inventory decreased to CNY 59,168,414.06 from CNY 67,044,790.50, indicating a decline of approximately 11.7%[17].